Experiment 623541
Worktypes
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Ginkgo biloba (GINKGOACEAE) |
| Citation | PETERS,H: KIISER,M: HOLSCHER,U:. (1998). DEMONSTRATION OF THE EFFICACY OF GINKGO BILOBA SPECIAL EXTRACT EGB 761 ON INTERMITTENT CLAUDICATION - A PLACEBO-CONTROLLED, DOUBLE-BLIND MULTICENTER TRIAL.. 27() |
| Amount utilized | |
| Compound isolated | |
| Disease | A MULTICENTRIC RANDOMIZED, PLACEBO CONTROLLED DOUBLE-BLIND STUDY ON GINKGO BILOBA SPECIAL EXTRACT EGB 761 (TEBONIN FORTE) IN PATIENTS SUFFERING FROM PERIPHERAL OCCLUSIVE ARTERIAL DISEASE (POAD) IN FONTAINE STAGE II-B WAS PERFORMED. IN TOTAL, 111 PATIENTS WITH ANGIOGRAPHICALLY PROVEN PAOD IN FONTAINE STAGE II-B AND INTERMITTENT CLAUDICATION (PAIN-FREE WALKING DISTANCE <150 M ON THE TREADMILL) WERE RECRUITED IN 5 CENTERS AND TREATED WITH EITHER EBG 761 OR PLACEBO AT A DAILY DOSE OF 3 X 1 FILM-COATED TABLETS OVER A DURATION OF 24 WEEKS, FOLLOWING A 2-WEEK PLACEBO RUN-IN PERIOD. THE PRIMARY RESPONSE VARIABLE WAS THE DIFFERENCE OF THE PAIN-FREE WALKING DISTANCE BETWEEN THE START OF TREATMENT AND AFTER 8, 16 AND 24 WEEKS AS MEASURED ON THE TREADMILL (WALKING SPEED 3 KM/H AND SLOPE OF 12%) UNDER STANDARDIZED CONDITIONS. AT THE START OF THE TREATMENT PERIOD, THE MEAN PAIN-FREE WALKING DISTANCES WERE VERY SIMILAR WITH 108.5 M IN THE EGB 761 GROUP AND 105.2 M IN THE PLACEBO GROUP. AT THE END OF THE TREATMENT PERIOD THESE VALUES INCREASED TO 153.2 M AND 126.6 M, RESPECTIVELY. |
| Dose amount | 120.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Extract | ACETONE-WATER(50:50) |
| Gender | GIVEN TO BOTH SEXES |